Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals' chief financial officer Eric Bjerkholt reported routine equity compensation activity. On January 21, 2026, 3,334 restricted stock units were converted into the same number of common shares at an exercise price of $0, increasing his directly held common stock to 43,548 shares. On January 22, 2026, he sold 1,421 common shares at a price of $93.3252 per share, leaving him with 42,127 common shares held directly. The filing notes that these shares were sold to cover tax withholding obligations tied to the vesting of the restricted stock units. Following the transactions, he also directly holds 6,666 restricted stock units, each representing the right to receive one share of common stock or its cash equivalent, with one-third of the award vesting annually from January 21, 2025 through the third anniversary.
Mirum Pharmaceuticals, Inc. executive Peter Radovich, the company’s President and COO, reported routine equity compensation activity. On January 21, 2026, 4,167 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0 per share. Each restricted stock unit represents a right to receive one share of common stock or its cash equivalent. Following this conversion, he held 23,061 shares of common stock, which includes 222 shares acquired under the company’s employee stock purchase plan.
On January 22, 2026, Radovich sold 2,382 shares of Mirum common stock at an average price of $93.3252 per share, with the shares sold to cover tax withholding obligations related to the RSU vesting. After the sale, he beneficially owned 20,679 shares of common stock directly, and 8,333 restricted stock units remained outstanding, scheduled to vest in equal annual installments through the third anniversary of January 21, 2025.
Mirum Pharmaceuticals, Inc. chief executive officer Christopher Peetz reported routine equity compensation activity and a related share sale. On January 21, 2026, 12,797 shares of common stock were acquired upon the vesting and settlement of restricted stock units, increasing his directly held common stock to 170,831 shares and his directly held restricted stock units to 25,593 units. On January 22, 2026, he sold 7,098 shares of common stock at $93.3252 per share, and the filing states these shares were sold to cover tax withholding obligations from the RSU vesting. After these transactions, he directly owns 163,733 shares of common stock and indirectly holds 187,500 shares of common stock through The Peetz Family Trust, in addition to the outstanding restricted stock units.
Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, reported equity award activity and a related share sale. On January 16, 2026, 12,500 restricted stock units vested and were converted into 12,500 shares of Mirum common stock at an exercise price of $0. Footnotes state that each unit represents one share and that one-third of the award vests on each anniversary of January 16, 2024 until fully vested after three years.
On January 20, 2026, Quan sold 6,911 shares of common stock at an average price of $90.2696 per share to cover tax withholding obligations tied to the vesting. After these transactions, she directly owned 11,305 shares of Mirum common stock and 12,500 restricted stock units.
Mirum Pharmaceuticals director Saira Ramasastry reported an option exercise and share sale in Mirum Pharmaceuticals, Inc. common stock. On January 15, 2026, she exercised a stock option for 2,000 shares of common stock at an exercise price of $23.51 per share and acquired 2,000 shares directly. That same day, she sold 2,000 shares of common stock at a price of $90.99 per share, leaving her with 0 shares of common stock held directly after the transactions.
The filing shows that the underlying stock option is fully vested and that 8,000 stock options remained beneficially owned following the reported activity. The sale was made pursuant to a Rule 10b5-1 trading plan that she adopted on September 18, 2025, indicating the transactions were carried out under a pre-established, automatic plan.
An affiliate of MIRM has filed a Rule 144 notice to sell 2,000 shares of common stock on NASDAQ through Morgan Stanley Smith Barney. These shares were acquired from the issuer via a stock option exercise for cash on 01/15/2026, the same date targeted for the sale. As context, the filing lists 51,393,574 shares of the issuer’s common stock outstanding.
Over the prior three months, the person named in the filing, Saira Ramasastry, sold 5,000 common shares on 12/22/2025 for gross proceeds of $400,000.00 and 2,000 common shares on 12/18/2025 for gross proceeds of $139,460.00.
Mirum Pharmaceuticals furnished a current report describing new investor information. The company issued a press release with preliminary unaudited net product sales for the year ended December 31, 2025, including sales for its liver disease medicines LIVMARLI (maralixibat), CHOLBAM and CTEXLI, along with preliminary unaudited cash, cash equivalents and investments.
Mirum also posted an updated corporate slide presentation on its website in connection with the J.P. Morgan Healthcare Conference, and furnished this presentation as an exhibit. Both the press release and the investor presentation are being furnished rather than filed, which means they are not automatically incorporated into other SEC reports unless specifically referenced.
Mirum Pharmaceuticals agreed to acquire Bluejay Therapeutics through a two-step merger, adding worldwide rights to brelovitug, a late-stage antibody for chronic hepatitis D and B. At closing Mirum will pay Target security holders an upfront $250 million in cash plus up to 5,196,009 Mirum shares, valued at about $370 million based on a recent volume-weighted average price, with up to $200 million in additional cash milestones tied to future net sales. The deal is subject to antitrust clearance, Bluejay shareholder approval and other customary conditions, with closing expected in the first quarter of 2026.
To help fund the transaction, Mirum arranged a $200 million private placement, selling 2,385,149 common shares and pre-funded warrants for 536,412 shares at $68.48 per share (or $68.4799 per warrant). The brelovitug program has FDA breakthrough therapy designation and EMA PRIME status for HDV and is in a global Phase 3 AZURE program, with key interim and top-line data readouts anticipated from 2026 through 2028. Mirum also highlighted upcoming clinical catalysts across volixibat, Livmarli and MRM-3379, including planned regulatory filings and potential launches if approvals are obtained.
Mirum Pharmaceuticals (MIRM) director reports option exercise and share sale. On 11/21/2025, the reporting person exercised a stock option for 50,000 shares of common stock at $2.936 per share and acquired the shares. On the same day, they sold 50,000 shares of common stock at $70 per share under a pre-arranged Rule 10b5-1 trading plan.
After these transactions, the director reported no directly held common shares, but continued to report indirect ownership of 186,410 shares through The Grey Family Trust dated November 12, 1999 and 93,750 shares through The Grey 2018 Irrevocable Children's Trust. They also reported 281,176 stock options beneficially owned following the transactions, with the option referenced in this filing fully vested and exercisable.
Mirum Pharmaceuticals, Inc. (MIRM) reported an insider equity transaction by its Chief Executive Officer, who is also a director. On 11/18/2025, the reporting person exercised an employee stock option to buy 19,133 shares of common stock at an exercise price of $19.24 per share, coded as transaction type "M" for an option exercise.
Following this transaction, the reporting person beneficially owns 158,034 shares of Mirum common stock directly and 208,570 shares indirectly through The Peetz Family Trust. The filing notes that the stock option involved in this transaction is fully vested and that the direct holdings include 260 shares acquired on November 10, 2025 under the company’s Employee Stock Purchase Plan.